A call for doubling the diagnostic rate of at-risk MASH

A new publication entitled “A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis” was released this week in The Lancet.

Currently, MASH affects 5% of the general population, and patients often show no symptoms until they reach an advanced stage, which can lead to cirrhosis or liver cancer.

Health experts are now calling for MASH diagnoses to double within the next two years so patients can receive timely treatment, improve their outcomes, and reduce the burden on the healthcare system.

Proposals to achieve this goal include routine screening of at-risk patients, integrating liver tests into regular health checkups, and updating reimbursement policies.

At Echosens, we are focused and committed as the leader in non-invasive liver tests to truly have a significant impact on increasing the diagnostic rate by making our FibroScan® solutions more accessible and easier-to-use upstream in the cardiometabolic and MASLD/MASH care pathway.